Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer-Reference-Cited by-同舟云学术

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Published:2021-02-03 Issue:17 Volume:27 Page:4870-4882
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

De Angelis Carmine,Fu Xiaoyong^ORCID,Cataldo Maria Letizia,Nardone Agostina,Pereira Resel,Veeraraghavan Jamunarani,Nanda Sarmistha,Qin Lanfang,Sethunath Vidyalakshmi,Wang Tao^ORCID,Hilsenbeck Susan G.^ORCID,Benelli Matteo^ORCID,Migliaccio Ilenia,Guarducci Cristina,Malorni Luca^ORCID,Litchfield Lacey M.,Liu Jiangang^ORCID,Donaldson Joshua,Selenica Pier,Brown David N.,Weigelt Britta,Reis-Filho Jorge S.,Park Ben H.,Hurvitz Sara A.,Slamon Dennis J.,Rimawi Mothaffar F.,Jansen Valerie M.,Jeselsohn Rinath^ORCID,Osborne C. Kent,Schiff Rachel^ORCID

Funder

Cancer Prevention & Research Institute of Texas

Conquer Cancer Foundation—Gianni Bonadonna Breast Cancer Research Fellowship

Breast Cancer Research Foundation

Breast Cancer Specialized Programs of Research Excellence

NIH

NCI Cancer Center Support

CPRIT

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-mediated lncRNA-induced immune cell plasticity in cancer immunopathogenesis;International Immunopharmacology;2024-11

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Estrogen receptor regulation of the immune microenvironment in breast cancer;The Journal of Steroid Biochemistry and Molecular Biology;2024-06

5. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy;npj Breast Cancer;2024-03-06